Guggenheim Maintains Buy on Beam Therapeutics, Lowers Price Target to $55

Benzinga · 05/07 15:21
Guggenheim analyst Debjit Chattopadhyay maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and lowers the price target from $78 to $55.